Gene Therapy · us
After Crossing the Blood-Brain Barrier, How Can Gene Editing Move Beyond a “One Disease, One Case” Model? US Funds Shared Platform for Pediatric Brain Disorders
A 12-party team led by the Broad Institute has received up to $34.5 million in support to combine an intravenously administered brain-delivery vector with base and prime editing, initially testing in two severe pediatric neurological diseases whether manufacturing, regulatory review, and clinical trial frameworks can be shared.
The challenge of treating rare pediatric brain disorders lies not only in how to correct disease-causing genes. Each disease—and even each variant—affects very few patients. If every therapy requires a new vector, manufacturing process, toxicology dataset, and clinical trial, ideas that are scientifically feasible may remain in the laboratory because of cost and time. The US Advanced Research Projects Agency for Health (ARPA-H) is now betting on another path: placing multiple therapies within a single, reusable development system.
The initiative, called PERC, the “Pediatric Epilepsy and Rare CNS Gene Editing Platform,” is led by the Broad Institute as the prime award recipient and brings together 12 research, clinical, manufacturing, regulatory, and patient organizations. ARPA-H information shows that the milestone-based program began on July 6, 2026, and will provide up to $34.5 million; the team’s goal is to advance to a first-in-human trial within three years.
PERC will initially target two severe developmental and epileptic encephalopathies: alternating hemiplegia of childhood associated with ATP1A3 variants, and Dravet syndrome, which is most often caused by SCN1A variants. The former can involve recurrent episodes of temporary paralysis, seizures, and developmental delay; the latter often presents in infancy with prolonged, difficult-to-control seizures and can cause lifelong disability. The consortium said the corresponding editing strategies have improved disease manifestations in animal models of both disorders, but there is currently no evidence of efficacy in humans.
The platform’s core combination consists of base-editing or prime-editing tools together with the TfR1 CapX adeno-associated virus vector, which can be delivered through intravenous infusion. This vector has been engineered to bind to human transferrin receptor 1 and cross the blood-brain barrier, with the aim of eliminating the need for intracerebral or intrathecal injection. Apertura Gene Therapy will provide the delivery technology; the Rare Disease Translational Center at The Jackson Laboratory will be responsible for disease models, therapy testing, and other preclinical work.
What will truly determine the platform’s value is not merely whether it can produce one candidate therapy for each of the two diseases, but whether different drugs can share biodistribution, toxicology, manufacturing, and regulatory data. ARPA-H requires the THRIVE team to demonstrate in the first year an evidence base that can be shared across multiple products and to plan an umbrella human trial capable of accommodating different products and disease phenotypes. If successful, subsequent rare neurological diseases may be able to reuse parts of the infrastructure instead of starting from scratch each time.
Background
This remains a high-risk clinical translation experiment. Although TfR1 CapX already has preclinical research behind it, the consortium does not expect to obtain early human safety data until later in 2026; whether its distribution in the brain will be sufficiently uniform, whether editing will occur in the correct cells, and whether immune responses and unintended edits can be controlled all remain to be verified. In addition, the two diseases may encompass multiple types of variants. Whether the same editing and delivery framework can genuinely support multiple products will be key to determining whether PERC can move beyond a single successful case.